List view / Grid view
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or…
16 February 2017 | By WITec
WITec presents a new operating concept with the powerful and intuitive Suite FIVE at Pittcon 2017...
16 February 2017 | By Niamh Marriott, Digital Editor
The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA), in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).
16 February 2017 | By Niamh Marriott, Digital Editor
The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range...
16 February 2017 | By Niamh Marriott, Digital Editor
Sophia Genetics announced that ten new genomic institutions from Latin America have started using SOPHiA to democratise access to clinical genomics...
13 February 2017 | By Niamh Marriott, Digital Editor
NICE published draft guidance recommending ponatinib (Iclusig, Incyte Corporation) for routine use on the NHS, to treat chronic myeloid leukaemia...
10 February 2017 | By Niamh Marriott, Digital Editor
Armetheon has reached agreement with the FDA for a single 1000 patient final pivotal trial for its drug candidate, tecarfarin, prior to filing an NDA...
9 February 2017 | By Niamh Marriott, Digital Editor
"It is our longstanding position that Amgen's asserted patent claims are invalid and we look forward to moving forward with the appeal process."
8 February 2017 | By Niamh Marriott, Digital Editor
Keele University stroke specialist Professor Christine Roffe is leading ground breaking clinical trials into a smart chip that could save lives.
8 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance recommending the Intrabeam Radiotherapy System (Carl Zeiss UK) for people with early breast cancer...
7 February 2017 | By Niamh Marriott, Digital Editor
Nanobiotix, a late clinical-stage nanomedicine company, announced the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer. Mr Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for their lead product NBTXR3, which could obtain a CE Mark approval in…
7 February 2017 | By Metrohm Appllikon
When it comes to monitoring industrial manufacturing processes, NIRS offers a rapid and reliable supplement to conventional titration methods...
6 February 2017 | By Metrohm
The Mira M-3 is the new handheld Raman spectrometer from Metrohm. Barely larger than a smartphone, the Mira M-3 enables true single-handed operation...
3 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has authorised Abbott’s molecular test to detect Zika virus in whole blood (when collected alongside a patient-matched serum or plasma sample) for emergency use. This is the first molecular test made by a commercial manufacturer authorised to detect Zika in whole blood samples;…
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
